Skip to main content
SpringerLink
Log in

Management of the Neutropenic Patient with Fever

  • Chapter
  • First Online:
Principles and Practice of Cancer Infectious Diseases

Part of the book series: Current Clinical Oncology ((CCO))

  • 1508 Accesses

Abstract

Neutrophils provide protection against a wide variety of common and opportunistic bacterial and fungal pathogens. Consequently, the frequency and severity of infections caused by these organisms is increased in patients with neutropenia. At most cancer treatment centers, Gram-positive organisms are isolated more frequently from neutropenic patients with documented bacterial infections than Gram-negative bacilli, although institutional and regional differences occur as do periodic shifts in the spectrum of bacterial infections. Candida spp. and Aspergillus spp. remain the most common fungal pathogens in this setting, although a number of opportunistic fungal pathogens have emerged. The prompt administration of empiric, broad-spectrum, parenteral antibiotics in the hospital when a neutropenic patient becomes febrile is the standard of care. Over the past decade, it has become possible to reliably identify “low-risk” neutropenic patients both in adult and pediatric patient populations. Infection prevention (prophylaxis), infection control, and antimicrobial stewardship are important aspects in the overall management of the febrile neutropenic patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 259.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–51.

    Article  PubMed  Google Scholar 

  2. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103–10.

    Article  PubMed  Google Scholar 

  3. Klastersky J, Ameye L, Maertens J, et al. Bacteremia in febrile neutropenic cancer patients. Internat J Antimicrob Agents. 2007;30S:551–9.

    Google Scholar 

  4. Yadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in cancer patients. Clin Infect Dis. 2003;37:1144–5.

    Article  PubMed  CAS  Google Scholar 

  5. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica. 2006;91:986–9.

    PubMed  Google Scholar 

  6. Klastersky J, Paesmans M, Rubenstein E, et al. The MASCC Risk Index: a multinational scoring system to predict low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.

    PubMed  CAS  Google Scholar 

  7. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988;148:2561–8.

    Article  PubMed  CAS  Google Scholar 

  8. Rolston K. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis. 1999;29:515–21.

    Article  PubMed  CAS  Google Scholar 

  9. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24:4129–34.

    Article  PubMed  CAS  Google Scholar 

  10. Innes HE, Smith DB, O’Reilly SM, et al. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single centre study. Br J Cancer. 2003;89:43–9.

    Article  PubMed  CAS  Google Scholar 

  11. Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol. 2008;26:606–11.

    Article  PubMed  Google Scholar 

  12. Cherif H, Johansson E, Björklholm M, Kalin M. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematolgia. 2006;91:215–22.

    Google Scholar 

  13. Rolston KVI, Bodey GP. Infections in patients with cancer. In: Kufe DW, Bast Jr RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei III E, editors. Cancer Medicine, e7. Hamilton, ON: BC Decker; 2006. p. 2222–45.

    Google Scholar 

  14. Rolston KVI, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45:228–33.

    Article  PubMed  Google Scholar 

  15. Elting LS, Bodey GP, Fainstein V. Polymicrobial septicemia in the cancer patient. Medicine. 1986;65:218–25.

    Article  PubMed  CAS  Google Scholar 

  16. Adachi JA, Yadegarynia D, Rolston K. Spectrum of polymicrobial bacterial infection in patients with cancer, 1975–2002. (Abstract 4). American Society for Microbiology. Polymicrobial Diseases. Lake Tahoe, NV, Oct. 19–23, 2003.

    Google Scholar 

  17. Rolston KVI, Tarrand JJ. Pseudomonas aeruginosa – still a frequent pathogen in patients with cancer: 11-year experience from a comprehensive cancer center. Clin Infect Dis. 1999;29:463–4.

    Article  PubMed  CAS  Google Scholar 

  18. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45:1602–9.

    Article  PubMed  Google Scholar 

  19. Han XY, Dé I, Jacobson KL. Rapidly growing mycobacteria. Clinical and Microbiologic studies of 115 cases. Am J Clin Pathol. 2007;128:612–21.

    Article  PubMed  Google Scholar 

  20. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997;24:1122–8.

    Article  PubMed  CAS  Google Scholar 

  21. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis. Candida glabrata and Candida krusei as the leading causes of Candidemia in hematologic malignancy. Cancer. 2008;112:2493–9.

    Article  PubMed  Google Scholar 

  22. Mullen CA, Abd El-Baki H, Samir H, Tarrand JJ, Rolston KV. Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients. Support Care Cancer. 2003;11:321–5.

    PubMed  CAS  Google Scholar 

  23. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine. 2000;79:250–60.

    Article  PubMed  CAS  Google Scholar 

  24. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematolgic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39:425–9.

    Article  PubMed  CAS  Google Scholar 

  25. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350:950–2.

    Article  PubMed  CAS  Google Scholar 

  26. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39:S32–7.

    Article  PubMed  Google Scholar 

  27. Santolaya ME, Alvarez AM, Avilés CL, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever and neutropenia. Clin Infect Dis. 2002;35:678–83.

    Article  PubMed  CAS  Google Scholar 

  28. Santolaya ME, Alvarez AM, Avilés CL, et al. Early hospital ­discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol. 2004;22:3784–9.

    Article  PubMed  Google Scholar 

  29. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol. 1994;12:107–14.

    PubMed  CAS  Google Scholar 

  30. Kern KV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis. 2006;15:533–40.

    Article  Google Scholar 

  31. Rolston KVI. Prediction of neutropenia. Int J Antimicrob Agents. 2000;16:113–5.

    Article  PubMed  CAS  Google Scholar 

  32. Hidalgo M, Hornedo J, Lumbreras JM, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. Cancer. 1999;85:213–9.

    Article  PubMed  CAS  Google Scholar 

  33. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low risk neutropenic cancer patients. Cancer. 1993;71:3640–6.

    Article  PubMed  CAS  Google Scholar 

  34. Rolston K, Rubenstein E, Elting L, Escalante E, Manzullo E, Bodey GP. Ambulatory management of febrile episodes in low-risk neutropenic patients [abstract LM81]. In: Program and Abstract of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology (Washington, DC). 1995.

    Google Scholar 

  35. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of febrile neutropenia in low risk pediatric cancer patients. Cancer. 1999;86:126–34.

    Article  PubMed  CAS  Google Scholar 

  36. Rolston KVI, Manzullo EF, Elting LS, et al. Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia. Cancer. 2006;106:2489–94.

    Article  PubMed  CAS  Google Scholar 

  37. Rolston KVI, Frisbee-Hume SE, Patel S, Manzullo EF, Benjamin RS. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer. 2009;18(1):89–94.

    Google Scholar 

  38. Escalante CP, Weiser MA, Manzullo E, et al. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer. 2004;12:657–62.

    PubMed  Google Scholar 

  39. Vidal L, Paul M, Ben Dor I, Soares-Weiser K, Liebovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother. 2004;54:29–37.

    Article  PubMed  CAS  Google Scholar 

  40. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597–607.

    Article  PubMed  CAS  Google Scholar 

  41. Cinetta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37:382–9.

    Article  Google Scholar 

  42. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988;108:30–5.

    Article  PubMed  CAS  Google Scholar 

  43. Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother. 2003;36:1062–7.

    Article  Google Scholar 

  44. Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2008;6:122–74.

    PubMed  Google Scholar 

  45. Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect. 2006;12:212–6.

    Article  PubMed  CAS  Google Scholar 

  46. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br Med J. 2003;326:1111–9.

    Article  CAS  Google Scholar 

  47. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338–48.

    Article  PubMed  CAS  Google Scholar 

  48. Elting LS, Rubenstein EB, Rolston K, et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol. 2000;18:3699–706.

    PubMed  CAS  Google Scholar 

  49. Pizzo PA, Robichard KJ, Gill FA. Duration of empiric antibiotic therapy in granulopenic patients with cancer. Am J Med. 1979;67:194–9.

    Article  PubMed  CAS  Google Scholar 

  50. Corey L, Boeckh M. Persistent fever in patients with neutropenia. N Engl J Med. 2002;346:222–4.

    Article  PubMed  Google Scholar 

  51. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st Century. Cancer. 2005;103:1103–13.

    Article  PubMed  Google Scholar 

  52. Rolston KVI. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40:S246–52.

    Article  PubMed  Google Scholar 

  53. Bad Bugs, No Drugs. Infectious Diseases Society of America. http://www.idsociety.org/pa/IDSA_Paper4_final_web.pdf. Accessed July 2004.

  54. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.

    Article  PubMed  Google Scholar 

  55. Metjian TA, Prasad PA, Kogon A, Coffin SE, Zaoutis TE. Evaluation of an antimicrobial stewardship program at a pediatric teaching hospital. Pediatr Infect Dis J. 2008;27:106–11.

    PubMed  Google Scholar 

  56. Paskovaty A, Pflomm JM, Myke N, Seo SK. A multidisciplinary approach to antimicrobial stewardship: evolution into the 21st century. Int J Anticrob Agents. 2005;25:1–10.

    Article  CAS  Google Scholar 

  57. Adachi J, Perego C, Vigil K, Mulanovich V, Chemaly R, Rolston K. Antibiotic stewardship initiative in the intensive care unit (ICU): evidence from a quality improvement project supporting the development of a multidisciplinary antimicrobial stewardship team (MAST). [Abst. #08-059]. In: Programs and abstracts of the Multinational Association for Supportive Care in Cancer (MASCC/ISOO) 2008 International Symposium, Houston, Texas, June 26–28, 2008.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Kenneth V. I. Rolston

Authors
  1. Kenneth V. I. Rolston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerald P. Bodey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth V. I. Rolston .

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, Infectious Diseases Department, The University of Texas, 800 5th Avenue, Apt. 12-G, New York, 10065, New York, USA

    Amar Safdar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Rolston, K.V.I., Bodey, G.P. (2011). Management of the Neutropenic Patient with Fever. In: Safdar, A. (eds) Principles and Practice of Cancer Infectious Diseases. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-644-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-644-3_8

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-643-6

  • Online ISBN: 978-1-60761-644-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation